Trial · NCT01972841
Adverse events330
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 330
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dry mouth | Gastrointestinal disorders | Placebo | 8 | 429 | |
| other | Dry mouth | Gastrointestinal disorders | Mirabegron 25 mg | 17 | 423 | |
| other | Dry mouth | Gastrointestinal disorders | Mirabegron 50 mg | 14 | 422 | |
| other | Dry mouth | Gastrointestinal disorders | Solifenacin 5 mg | 25 | 423 | |
| other | Dry mouth | Gastrointestinal disorders | Solifenacin 5 mg + Mirabegron 25 mg | 72 | 853 | |
| other | Dry mouth | Gastrointestinal disorders | Solifenacin 5 mg + Mirabegron 50 mg | 60 | 848 | |
| serious | Appendicitis | Infections and infestations | Placebo | 0 | 429 | |
| serious | Appendicitis | Infections and infestations | Mirabegron 25 mg | 0 | 423 | |
| serious | Appendicitis | Infections and infestations | Mirabegron 50 mg | 1 | 422 | |
| serious | Appendicitis | Infections and infestations | Solifenacin 5 mg | 0 | 423 | |
| serious | Appendicitis | Infections and infestations | Solifenacin 5 mg + Mirabegron 25 mg | 0 | 853 | |
| serious | Appendicitis | Infections and infestations | Solifenacin 5 mg + Mirabegron 50 mg | 1 | 848 | |
| serious | Bronchitis | Infections and infestations | Placebo | 1 | 429 | |
| serious | Bronchitis | Infections and infestations | Mirabegron 25 mg | 0 | 423 | |
| serious | Bronchitis | Infections and infestations | Mirabegron 50 mg | 0 | 422 | |
| serious | Bronchitis | Infections and infestations | Solifenacin 5 mg | 0 | 423 | |
| serious | Bronchitis | Infections and infestations | Solifenacin 5 mg + Mirabegron 25 mg | 0 | 853 | |
| serious | Bronchitis | Infections and infestations | Solifenacin 5 mg + Mirabegron 50 mg | 1 | 848 | |
| serious | Bronchopneumonia | Infections and infestations | Placebo | 0 | 429 | |
| serious | Bronchopneumonia | Infections and infestations | Mirabegron 25 mg | 0 | 423 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01972841/events